Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is the first study in people to test a new drug called NXP900 for advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. The study will also look for early signs that the drug can shrink tumors, especially in cancers with speci…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for lung cancer patients who stopped responding to standard treatment
Disease control Recruiting nowThis early-stage study is testing whether adding an experimental drug called NXP900 to a standard lung cancer medication (osimertinib) can help control advanced lung cancer that has started growing again. The trial will enroll about 18 adults whose cancer has a specific genetic c…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC